Clinical Trial Update: Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on the safety and tolerability of AL-001 ophthalmic injections in patients with wet age-related macular degeneration; study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• AL-001

Snippet

Sponsor: Beijing Anlong Biopharmaceutical Co., Ltd. | Conditions: Wet Age-related Macular Degeneration (wAMD) | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING